About this episode
In The Tox Talks we feature expert injectors with significant experience using botulinum toxins. We explore their experience with particular brands, how their techniques have evolved and the subtle nuances of getting the best out of toxins.
In Chapter 6 we focus on a newly launched product, Letybo (letibotulinumtoxinA) by Hugel Aesthetics. Also known as Botulax, it has been used in Asian markets since 2009. Our guest, Professor Syed Haq, divides his time between preventative medicine and aesthetics. He has sat on advisory boards for Ipsen and Allergan Aesthetics and is a Hugel Aesthetics KOL for Letybo.
We discuss the evolution of neurotoxins, manufacturing and safety, clinical trial evidence and comparisons, patient selection, injection technique and depth, placebo and nocebo effects, dosing patterns for the frontalis and lower face, managing expectations, explaining a new toxin to patients, and pricing.
What you'll learn
- What Letybo is and how it compares to other toxins
- What the clinical trial evidence shows
- Why toxin results vary between patients
- How placebo and nocebo effects influence outcomes
- How to introduce a new toxin to your patients
Topics
- The Tox Talks
- Botulinum toxin
- Letybo
- Hugel
- Pricing
- UK
Full transcript
The full transcript for this episode is coming soon.